Radiation before CAR T therapy for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older, and you can consent (or your legal representative can).
- You have large B-cell lymphoma confirmed by biopsy and it has relapsed or is refractory.
- You must be scheduled to receive a commercial CAR T-cell infusion within 3 months of joining.
- Your lymphoma shows up on PET scan in up to 6 treatable sites (with up to 3 radiation “isocenters”).
- You have measurable disease on imaging (tumor size criteria on CT/MRI) and you are recovered from recent treatment side effects (except hair loss).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
This trial tests whether adding a targeted antibody (rituximab) before CAR T cell therapy improves outcomes for patients with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.